OncoMatch/Clinical Trials/NCT04910802
Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden
Is NCT04910802 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Gardasil9 for hpv infection.
Treatment: Gardasil9 — The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered to all resident women aged 22-27 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cervical Cancer
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04910802 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 27 years or younger and at least 22 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages